Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00684073
Other study ID # P05094
Secondary ID 2006-006686-17
Status Completed
Phase Phase 4
First received
Last updated
Start date July 2007
Est. completion date December 2007

Study information

Verified date March 2023
Source Indivior Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to determine if opioid dependent subjects who are already receiving Subutex® prefer the Suboxone® tablet over the Subutex® tablet after switching from Subutex® to Suboxone®. Subjects who are selected to participate in this study will continue their prescribed dose of Subutex® (buprenorphine 2 to 16 mg daily) for the first two days of the study (Day 1 and Day 2) then switch to and receive an equivalent dose of Suboxone® (buprenorphine 2 to 16 mg daily) for the last 3 days of the study (Day 3, Day 4 and Day 5). The Day 5 Visit will be the subject's last study visit. Upon completing the study, subjects will continue their pre-study prescribed dosage of Subutex®.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date December 2007
Est. primary completion date December 2007
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subject must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent. - Subject must be at least (>=) 18 years of age, of either sex. - Subject treated for opioid dependence with Subutex® with a stable daily dose between 2 mg and 16 mg daily, for at least 6 months. - Subject who do not inject/misuse their treatment with Subutex®. - Subject must be free of illicit opiate drug use as assessed by urine test performed prior to inclusion. - Subject must understand and be able to adhere to the dosing and visit schedules, and agree to report concomitant medications / products and adverse events to the investigator or designee. - Women of childbearing potential (includes women who are less than one year postmenopausal and women who become sexually active) must be using or agree to use an acceptable method of birth control (e.g., hormonal contraceptive, medically prescribed IUD, condom in combination with spermicide) or be surgically sterile (e.g., hysterectomy or tubal ligation). - Women of childbearing potential should be counseled in the appropriate use of birth control while in this study. Women who are not currently sexually active must agree and consent to use one of the above-mentioned methods should they become sexually active while participating in the study. Women of childbearing potential must have a urine pregnancy test with negative result within 2 weeks prior to inclusion (as performed under control of the investigator or designee). Exclusion Criteria: - Subject not eligible for treatment with Subutex® or Suboxone® according to the legal drug attachments. - Subject refusing to take the daily dose of the study medication under control in the center. - Subject unable to complete the evaluations. - Women who are pregnant or nursing. - Subject with a history of hypersensitivity to buprenorphine hydrochloride or naloxone hydrochloride dihydrate or any excipient of Subutex® or Suboxone®. - Subject with a current evidence of alcohol abuse. - Subject with severe respiratory dysfunction, severe hepatic dysfunction, acute alcohol intoxication or delirium tremens . - Subject with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption. - Initiation or increase in the dose, within the past 7 days or scheduled during the study, of a treatment with: - benzodiazepines, - other depressants of the central nervous system: other morphine derivatives (analgesics, antitussives), certain antidepressive agents, sedative H1 antihistamines, barbiturates, benzodiazepines, anxiolytics other than benzodiazepines, neuroleptics, clonidine and clonidine-like agents and monoamine oxidase [MAO] inhibitors, - CYP3A4 inhibitors, - CYP3A4 inducers. - Subjects who have any current evidence of clinically significant hematopoietic, metabolic, cardiovascular, immunologic, neurologic, hematological, gastrointestinal, hepatic, renal, psychiatric, cerebrovascular, or respiratory disease, or any other disorder which, in the judgment of the investigator, may interfere with the study evaluations or affect subject safety. - Subjects who have used any investigational product within 30 days prior to enrollment. - Subjects participating in another trial at the same time. - Subject who intend to donate blood during the study or within 3 months after study completion. - Subjects in the exclusion period of the "Fichier National des Personnes qui se Prêtent à des Recherches Biomédicales" (National Index of Persons Participating in Biomedical Researches, or National Index of Volunteers).

Study Design


Intervention

Drug:
buprenorphine
2 mg buprenorphine and 8 mg buprenorphine tablets at doses from 2 to 16 mg buprenorphine daily for first two days of study
buprenorphine/naloxone
2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone tablets at doses from 2/0.5 mg buprenorphine/naloxone to 16/4 mg buprenorphine/naloxone daily for last 3 days of study

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Indivior Inc.

Outcome

Type Measure Description Time frame Safety issue
Primary Subject's Self Assessment Using 10 cm Visual Analogue Scale (VAS) of Overall Preference for One of the Two Buprenorphine-based Maintenance Therapies (Suboxone® or Subutex®). Score of 0 = "Not satisfied at all"; Score of 10 = "Totally satisfied" Each treatment Day (post-dose on days 1-5)
See also
  Status Clinical Trial Phase
Completed NCT02282306 - Phone Interview to Prevent Recurring Opioid Overdoses N/A
Completed NCT02224508 - Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks N/A
Completed NCT02375516 - Preventing Drug Abuse Among Hispanic Adolescents N/A
Withdrawn NCT01275391 - cSBIRT to Reduce Teen Tobacco, Alcohol and Drug Use Phase 1/Phase 2
Completed NCT01442753 - Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth N/A
Completed NCT00907309 - Dental and Medical Office iMET to Reduce Teen Tobacco, Alcohol, and Drug Use Phase 1/Phase 2
Completed NCT02228044 - Alcohol, Suicide and HIV Prevention for Teens in Mental Health Treatment N/A
Withdrawn NCT01427465 - Brief Integrative Alcohol Interventions for Adolescents N/A
Completed NCT00350909 - Brief Intervention for Drug Abusing Adolescents Phase 2
Completed NCT00148031 - Improving Hepatitis C Treatment in Injection Drug Users Phase 4
Completed NCT00383838 - Self-Selected Brief Alcohol Intervention for Adolescents N/A
Completed NCT00451854 - Student Athlete Testing Using Random Notification N/A
Completed NCT00722644 - Cognitive Behavioral Stress Management for HIV+ Drug Abusers Phase 1
Completed NCT01036711 - Effects of Nicotine on Cognitive Task Performance and Brain Activity as Measured by fMRI
Terminated NCT02741076 - Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain Phase 4
Completed NCT01035723 - Effect of Functional Genetic Polymorphisms on Brain Morphology and Function
Completed NCT06044363 - Satir Model for Self-esteem, Mental Health, and Family Function Among Individuals With Substance Use Disorders N/A
Recruiting NCT05037487 - Evaluation of Smoked THC and CBD in Men and Women Phase 1
Recruiting NCT04725266 - A Family-based Intervention for Drug-abusing Adults in Hong Kong N/A
Completed NCT03678051 - CBT4CBT for Women in Residential Treatment for Substance Use Disorders N/A